Abstract: In the last few decades, epigenetics has emerged as an exciting new field in development and disease, with a more recent focus towards cancer. Epigenetics has classically referred to heritable patterns of gene expression, primarily mediated through DNA methylation patterns. More recently, it has come to include the reversible chemical modification of histones and DNA that dictate gene expression patterns. Both the epigenetic up-regulation of oncogenes and downregulation of tumor suppressors have been shown to drive tumor development. Current clinical trials for cancer therapy include pharmacological inhibition of DNA methylation and histone deacetylation, with the aim of reversing these cancer-promoting epigenetic changes. However, the DNA methyltransferase and histone deacetylase inhibitors have met with less than promising results in the treatment of solid tumors. Regions of hypoxia are a common occurrence in solid tumors. Tumor hypoxia is associated with increased aggressiveness and therapy resistance, and importantly, hypoxic tumor cells have a distinct epigenetic profile. In this review, we provide a summary of the recent clinical trials using epigenetic drugs in solid tumors, discuss the hypoxia-induced epigenetic changes and highlight the importance of testing the epigenetic drugs for efficacy against the most aggressive hypoxic fraction of the tumor in future preclinical testing.
1. Cancer Epigenetics

The building blocks of chromatin are nucleosomes. Each nucleosome constitutes 146 base-pairs of DNA wound around a histone octamer consisting of histones H2A, H2B, H3 and H4. Nucleosomes are connected by linker DNA and the linker histone H1, extending the length of nucleosomal DNA to approximately 16–180 base-pairs. This “beads on a string” arrangement of nucleosomes is further condensed into secondary and tertiary levels of compaction (the so-called 30 and 100 nanometer fibers), with progressively higher levels of compaction culminating in the familiar mitotic chromosome. This enables the compression of meters of DNA into a single cell while also permitting dynamic changes in chromatin structure, which is necessary to balance the need for cellular packaging with the mobilization-essential functions including transcription, replication and repair [1]. Regions of chromatin can maintain either an open conformation called euchromatin, which is associated with active transcription, or closed conformation known as heterochromatin, which is associated with gene-repression [2]. The maintenance of euchromatin and heterochromatin is dictated by epigenetic mechanisms, which include changes in DNA methylation and histone modifications. Generally, DNA hypermethylation and histone H3K9, H3K27 and H4K20 methylation are associated with gene-repression, which refers to the reversible decrease in gene expression [3,4]. DNA hypermethylation and H3K27me3, however, can also be associated with gene-silencing, which is the long-term inhibition of gene expression [5–7]. On the other hand, DNA hypomethylation, methylation of H3K4 and H3K36, and acetylation of H3 and H4, generally mark areas of active gene expression [3,4], although H3K36 methylation can also be associated with methylated CpG islands, a repressive mark [8]. Emerging evidence has established a significant role for epigenetic changes in promoting cancer [3]. Epigenetic regulation may directly affect carcinogenesis [9], metastasis [10], drug resistance [11] and relapse [12]. Ascertaining which epigenetic changes are cancer-associated and how these changes promote cancer, are critical to designing strategies to reverse the cancer-associated epigenetic changes for cancer therapy.

Abnormalities in the epigenome arising from changes in promoter region CpG methylation and histone post-translational modifications can lead to dysregulated gene expression in cancer cells. The epigenetic repression of tumor suppressors, *Breast cancer 1* (*BRCA1*); *PYRIN-PAAD-DAPIN domain (PYD)* and *caspase-recruitment domain (CARD) domain containing (PYCARD)* which encodes Apoptosis-associated speck-like protein containing a *CARD* (ASC); and *Suppressor of Cytokine Signaling (SOCS)*, can greatly contribute to cancer progression [13–15]. The repression of these tumor suppressors was attributed to DNA hypermethylation and histone hypoacetylation [13–15]. Additionally, candidate tumor suppressors *retinoic acid receptor responder (tazarotene induced) 1* (*RARRES1*), which encodes Tazarotene-induced gene-1 *TIG1*; *Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila) (DAB2)*; *Ras association (RalGDS/AF-6) domain family member 1* (*RASSF1*); and *FEZ family zinc finger 2* (*FEZF2*) were shown to be down-regulated through a DNA hypermethylation-mediated mechanism in nasopharyngeal carcinoma [16–19]. The down-regulation of tumor suppressors can lead
to the outgrowth of tumor cells. Re-expressing the repressed or silenced tumor suppressors by pharmacologically reversing the cancer-associated epigenetic changes, may induce cancer cell death or sensitize the cancer cells to chemo- or radio-therapy [20], making epigenetic drugs a suitable approach to the treatment of cancer.

2. Targeting Cancer Epigenetics

As DNA hypermethylation has been linked to cancer progression, clinical studies have focused on inhibitors of DNA methyltransferases (DNMT) as a potential therapeutic approach to reverse this cancer-promoting epigenetic change (Figure 1) [21,22]. DNMTs targeted by these inhibitors include DNMT1, DNMT3a and DNMT3b. DNMT1 functions as the maintenance methyltransferase, recognizing 5-methyl-cytosine on the parent strand during DNA replication and methylating the daughter strand. In contrast, DNMT3a and DNMT3b are considered to be de novo methyltransferases, and can establish novel methylation patterns [21]. The DNMT inhibitors tested thus far include 5-Azacytidine and Decitabine. 5-Azacytidine, a nucleoside-analog, incorporates into the DNA during replication and covalently binds to DNMTs, thus reducing the pool of available DNMTs and effectively leading to DNMT inhibition [23]. 5-Azacytidine also has the ability to reverse gene-silencing by affecting histone methylation, for instance, by specifically reducing H3K9me2 and increasing H3K4-methylation at the p14ARF/p16INK4a locus [24]. Decitabine was subsequently developed as potentially a more potent analog of 5-Azacytidine, given that Decitabine can be more readily incorporated into DNA instead of both DNA and RNA [7]. Decitabine has proven to be more efficacious against the L1210 leukemia cells both in vitro and in vivo experimental designs [25]. However, the toxicities associated with Decitabine, in particular febrile neutropenia, remains an issue for the use of Decitabine in the clinic [7]. Developing more specific derivatives of the DNMT inhibitors with reduced toxicity would be beneficial for future clinical studies.

**Figure 1.** Epigenetic drugs in cancer therapy. A simplified schematic of the effects of DNA methyltransferase inhibitors (DNMTi) and histone deacetylase inhibitors (HDACi) on cancer progression.
DNA methylation is directly linked with histone deacetylation, as DNMT1 has been shown to interact with the histone deacetylase (HDAC) HDAC1 [26,27]. HDAC1 belongs to a larger family of enzymes, which removes the acetylation mediated by histone acetyltrasferases [28]. An interaction between DNMT1 and HDAC1 can result in genes consisting of both hypermethylated DNA and hypoacetylated histones. Akin to DNA hypermethylation, hypoacetylation of histones H3 and H4 have also been linked to cancer progression [13–15]. As a result, HDAC inhibitors that result in increased histone acetylation have also been considered as a potential epigenetic therapy in cancer treatment (Figure 1) [21,22]. These HDAC inhibitors were designed to reverse histone deacetylation-mediated repression of tumor suppressors. HDAC inhibitors include hydroxamic acids (Vorinostat, Panobinostat, Belinostat), cyclic tetrapeptides (Romidepsin), short chain fatty acids (Valproic acid), and benzamides (Entinostat) [29].

DNMT and HDAC inhibitors have shown promising results against hematological malignancies. Decitabine has been FDA-approved for acute myeloid leukemia (AML) [30], Vorinostat and Romidepsin have been FDA approved for the treatment of cutaneous T cell lymphoma [31], and Romidepsin and Belinostat have passed FDA approval for peripheral T cell lymphoma [32]. However, it is notable that these epigenetic drugs have met with less success against solid tumors (Table 1). Based on studies in hematological malignancies, it has been suggested that using a lower dosage of the DNMT inhibitors, 5-azacytidine and Decitabine, may prove to be more beneficial in solid tumors [30]. Determining optimal biological dose instead of utilizing the maximum-tolerated dose may lead to reduced toxicity while providing sufficient anti-tumor effects [30]. Combination therapy of certain HDAC inhibitors such as Vorinostat and Belinostat, with chemotherapeutic agents has shown more positive results relative to monotherapy [33,34], and this provides further avenues in therapeutic strategies against solid tumors. Identifying prognostic biomarkers may also prove to be beneficial in selecting appropriate candidates for epigenetic therapy [34]. However, a key difference in hematological malignancies and solid tumors is the abnormal vascularization observed in solid tumors, and the associated solid tumor microenvironment [35]. Understanding the solid tumor microenvironment is pivotal to advancing the use of epigenetic drugs in solid tumor treatment.

**Table 1.** Clinical trials with epigenetic drugs in solid tumors. Summarizing the results of clinical studies using epigenetic drugs against solid tumors. The drug and epigenetic mark targeted along with the clinical phase and outcome of the trial are provided. NSCLC = Non-small cell lung cancer; CR = Complete response; PR = Partial response; SD = Stable Disease.

| Drug | Drug Targets | Trials | Combined Therapy | Cancer | Outcome | Reference |
|------|--------------|--------|------------------|--------|---------|-----------|
| Vorinostat | HDAC | Phase II | Monotherapy | relapsed or refractory breast, colorectal NSCLC; metastatic breast cancer; platinum-refractory ovarian or primary peritoneal carcinoma | Toxocities observed, including Grade 3. No responses observed. | [36–39] |
| | | Phase II | carboplatin and paclitaxel | advanced-stage NSCLC | confirmed response rate of 34% *versus* 12.5% with placebo *(p = 0.02)* | [40] |
Table 1. Cont.

| Drug       | Drug Targets | Trials       | Combined Therapy       | Cancer                                      | Outcome                                                                 | Reference |
|------------|--------------|--------------|------------------------|---------------------------------------------|-------------------------------------------------------------------------|-----------|
| Romidepsin | HDAC 1 and 2 | Phase II     | Monotherapy            | metastatic renal cell cancer                | 1 CR and 1 PR in 29 evaluable patients, overall response rate of 7%     | [41]      |
|            |              |              |                        | lung cancer; colorectal cancer;              | No objective or minimal responses observed                               | [42–45]  |
|            |              | Phase II     | Monotherapy            | castration-resistant prostate cancer; small cell lung cancer |                                                                         |           |
| Belinostat | HDAC         | Phase II     | solid tumors           | Monotherapy trials not very successful but in combination with chemotherapy (Carboplatin and Paclitaxel) showed benefits | [34]      |
| Panobinostat | HDAC       | Phase II     | thymic carcinomas      | No objective response                       | [46]      |
| Entinostat | HDAC 1 and 3 | Phase II     | refractory renal carcinoma | No objective response                     | [47]      |
|            |              | Bortezomib   | advanced pancreatic cancer | No objective response                     | [48]      |
|            |              | Phase II     | metastatic melanoma    | No objective response                       | [49]      |
|            |              | Erlotinib    | advanced NSCLC         | No objective response                       | [50]      |
|            |              | Azacytidine  | metastatic NSCLC       | 1 CR and 1 PR; 4 of 19 patients had objective responses to future treatments | [51]      |
| Valproic acid | HDAC I and IIa | Phase II    | Hydralazine and chemotherapy | various carcinomas                     | 4 PR and 8 SD of 15 patients evaluable for response | [52] |
|            |              | Phase III    | Hydralazine and Cisplatin-topotecan | advanced cervical cancer | Better objective responses observed with combination therapy | [53] |
| 5-Azacytidine | DNMT       | Phase I      | Erlotinib               | solid tumors                               | Recommended dose/schedule for Phase II                                 | [54]      |
|            |              | Phase                  | Monotherapy            | epithelial ovarian                         | 1 CR, 3 PR and 10 SD in the 29 evaluable patients                     | [55]      |
| Decitabine  | DNMT         | Phase I       | Carboplatin             | solid tumors                               | Recommended dose/schedule for Phase II                                 | [56]      |
|            |              | Phase II     | Cisplatin               | squamous cell carcinoma of cervix           | 38.1% PR, 23.8% SD; Significant toxicities observed including Grade III and IV neutropenia | [57]      |

3. The Hypoxic Tumor Microenvironment

The microenvironment of solid tumors is characterized by regions of low oxygen (hypoxia), which plays a pivotal role in tumor progression. Tumor hypoxia arises from the high rate of tumor growth that cannot be sustained by a limited oxygen supply (Figure 2). Hypoxia is linked to increased aggressiveness of the tumor, and resistance to all available modalities of cancer treatment, including chemotherapy, radiotherapy and indirectly surgery [35,58,59]. Importantly, numerous studies demonstrate that tumor hypoxia correlates with poor patient prognosis [58,60].
Figure 2. Tumor microenvironment and hypoxia. The majority of solid tumors are characterized by abnormal tumor vasculature. When the high rate of tumor growth cannot be sustained by tumor angiogenesis, this causes limited oxygen supply to the tumor cells distal to the blood vessels, forming regions of hypoxia. Hypoxic tumor cells exhibit increased aggressiveness and metastasis, and are resistant to radiation and chemotherapy.

Hypoxia leads to the induction of the oxygen-sensitive master regulator Hypoxia Inducible Factor (HIF) family of transcription factors, which take control of the cellular response to hypoxia [61]. HIF transcription factors bind to hypoxia response elements (HRE) in target genes to mediate transcriptional activation (Figure 3). The HIF heterodimer is composed of an oxygen-labile HIFα (either HIF1α, HIF2α or HIF3α) and the constitutively expressed HIF1β. In the presence of oxygen, HIFα is hydroxylated by a family of dioxygenases called Prolyl-hydroxylases (PHDs), and this hydroxylated form of HIFα undergoes ubiquitination by the Von Hippel Lindau (VHL) E3 ubiquitin ligase complex, targeting it for proteasomal degradation [62,63]. Additionally, HIF transcriptional activity requires interaction with the transcriptional coactivator p300/CBP among other factors, and this interaction can be blocked by an oxygen-dependent protein called Factor Inhibiting HIF1 (FIH) [64]. In the presence of oxygen, FIH hydroxylates HIF1 and prevents its interaction with p300/CBP, thereby blocking the transcriptional activation of HIF targets [64].

The HIF family of transcription factors regulate many functions, including angiogenesis, metastasis, metabolism, survival and apoptosis [62]. HIF mediates transcriptional activation of a plethora of genes including, glucose transporter protein type 1 (GLUT1), vascular endothelial growth factor (VEGF), BCL2/adenovirus E1B 19kDa interacting protein 3 (BNIP3) and lysyl oxidase (LOX) [65,66], which are involved in a variety of cellular functions that promote tumor progression. For instance, GLUT1 mediates cellular glucose uptake and is important for glycolytic metabolism [66], and VEGF plays a key role in angiogenesis and tumor vascularization [67]. HIF-induced LOX expression promoted hypoxia-induced metastasis and has been linked with poor patient prognosis in breast cancer, head and neck cancer and various squamous cell carcinomas [68–71]. For a detailed understanding of HIF regulation and activity, please see reviews by Nguyen et al., Luo et al. and Rankin et al. [62,65,66]. Any attempts to specifically target epigenetic mechanisms in hypoxic tumors should account for both the transcriptional and biochemical perturbations imposed by the HIF regulatory axis [62].
Figure 3. Regulation of HIF family of transcription factors. HIF binds to hypoxia response elements (HRE) to activate transcription of the target genes. The HIF heterodimer is composed of a HIFα subunit and HIF1β subunit. HIFα is oxygen-sensitive and regulated by Prolyl-hydroxylases (PHD) and Factor Inhibiting HIF1 (FIH). In normoxia (at physiological oxygen levels) HIF1α is hydroxylated by PHD proteins leading to Von Hippel Lindau (VHL)-mediated ubiquitination of HIF1α and its subsequent degradation by the proteasome. In normoxia, FIH also mediates hydroxylation of HIF1α, preventing its interaction with p300/CBP, which is required for HIF-mediated transactivation. The oxygen-dependent PHDs and FIH are rendered inactive in hypoxic conditions leading to HIF1α stabilization. HIF1α stability also requires histone deacetylase (HDAC) activity, which can be blocked by HDAC inhibitors that lead to HIF1α destabilization. Under hypoxic stress, HIF1α is stabilized and it interacts with HIF1β and p300/CBP, and the complex binds to HRE to mediate transcriptional activation of hypoxia response genes, including BNIP3, LOX, VEGF, JmjC demethylases and TET1 hydroxylase. Although BNIP3 is a HIF target, DNA hypermethylation can block the HIF-mediated transcriptional activation of BNIP3. Although some JmjC demethylases and TET1 hydroxylase may be HIF targets, under severe hypoxia, certain members of these dioxygenase proteins may be rendered inactive due to their functional dependency on oxygen.

4. Hypoxia-Induced Epigenetics

Hypoxic tumor cells display a distinct epigenetic profile. Indeed, changes in histone acetylation have been associated with the hypoxic cellular response (Table 2). Hypoxic cells display a decrease in the levels of histone acetylation, and an associated global transcriptional repression [72]. HDAC expression and activity have been shown to be up-regulated in hypoxia, although the mechanism was not investigated [73]. HDAC1 up-regulation was linked to decreased transcription of tumor suppressors p53 and VHL upon exposure to 1% oxygen, and this correlated with increased expression of HIF1α, VEGF...
and angiogenesis [73]. A decrease in histone acetylation on H3K9 in particular, has been associated with down-regulation of genes including tumor suppressors BRCA1, RAD51, runt-related transcription factor 3 (RUNX3), p53 and VHL in hypoxia [13,73–75].

**Table 2.** Epigenetic alterations in hypoxia. Genes that are transcriptionally repressed at hypoxic conditions are regulated by various histone modifications.

| Gene    | Function                        | Transcription | Histone Mark altered in hypoxia                                      | Reference |
|---------|---------------------------------|---------------|---------------------------------------------------------------------|-----------|
| MLH1    | Tumor suppressor                | Repressed     | H3K4-demethylation                                                  | [76]      |
| -       |                                 |               | H3K9me2                                                             |           |
| -       |                                 |               | H3K9-hypoacetylation                                                |           |
| -       |                                 |               | H3K9me3                                                             |           |
| BRCA1   | Tumor suppressor                | Repressed     | H3K4-hypomethylation                                                | [75]      |
| -       |                                 |               | H3K9-hypoacetylation                                                |           |
| -       |                                 |               | H3K9-methylation                                                    |           |
| RAD51   | Tumor suppressor                | Repressed     | H3K4-hypomethylation                                                | [75]      |
| -       |                                 |               | H3K9-hypoacetylation                                                |           |
| -       |                                 |               | H3K9-methylation                                                    |           |
| RUNX3   | Tumor suppressor                | Repressed     | H3K9me2                                                             | [74]      |
| -       |                                 |               | Increased HDAC                                                      |           |
| Tp53    | Tumor suppressor                | Repressed     | Increased HDAC                                                      | [73]      |
| VHL     | Tumor suppressor                | Repressed     | Increased HDAC                                                      | [73]      |
| BNIP3   | Tumor suppressor                | Repressed     | DNA hypermethylation                                                | [77,78]  |
| APAK    | Negative regulator of p53       | Repressed     | H3K9me3                                                             | [79]      |
| PP2A-C  | Negative regulator of ATM       | Repressed     | H3K9me3                                                             | [80]      |
| FANCD2  | Fanconi anemia pathway          | Repressed     | Not Tested                                                          | [81]      |

Along with histone hypoacetylation, DNA hypermethylation may also contribute to gene-silencing under hypoxic conditions (Table 2). Hypermethylation of CpG dinucleotides in the promoter region can block HIF-mediated transcriptional activation of certain targets in hypoxic cells. BNIP3, which regulates hypoxia-induced cell death, was found to be repressed by DNA methylation in pancreatic, colorectal and gastric cancer [77,78]. CAIX overexpression has been associated with promoter DNA hypomethylation in gastric cancer, and CAIX expression correlates with tumor advancement and metastasis [82]. Of the PHD proteins, which negatively regulate HIF1α, PHD3 was shown to be regulated by DNA hypermethylation, while PHD1, PHD2 and FIH promoter regions did not display associated methylation changes in hypoxia [83,84].

Contrary to the hypoxia-induced DNA hypermethylation observed at certain loci, hypoxia has been linked to a global reduction in DNA methylation. HIF-dependent methionine adenosyltransferase II, alpha (MAT2A) induction caused reduced levels of S-adenosylmethionine, the methyl donor required for DNA methylation, leading to reduced methylation of CpG islands in hepatocellular carcinoma [85]. Hypoxia led to the down-regulation of DNA methyltransferases including DNMT1, DNMT3a and DNMT3b in colorectal cancer cells [86], and a global decrease in DNA methylation [87]. Hypoxia has also been linked with the HIF-dependent up-regulation of the Ten-eleven translocation (TET) dioxygenase TET1, which catalyzes the hydroxylation of 5-methyl-cytosine to 5-hydroxy-methyl-cytosine, in tumorogenic N-type neuroblastoma cells exposed to 1% oxygen [88]. TET1 activity essentially leads to
DNA demethylation and production of 5-hydroxy-methyl-cytosine, a modification that is associated with active transcription [88]. Hypoxia-induced TET1 up-regulation leading to global DNA hypomethylation, was also demonstrated in scleroderma fibroblasts, in a HIF-independent manner [89]. However, in severely hypoxic conditions, the lack of oxygen may render the oxygen-dependent TET enzymes inactive, and this decreased TET activity may explain the localized hypermethylation observed at specific loci in hypoxia, although this remains to be tested. Although DNA methylation may play a role in gene expression in hypoxia, given that hypoxia is linked to a global decrease in DNMTs and DNA methylation [86,87], it is unlikely to be the predominant epigenetic means of regulating gene expression under conditions of low oxygen.

Recent studies have demonstrated that oxygen levels significantly influence a change in another epigenetic mark, histone methylation, which is distinct from DNA methylation. Hypoxia has been linked to a decrease in the levels of the active histone mark H3K4me3, and an increase in the levels of the repressive marks H3K27me3, H3K9me2 and H3K9me3, at specific genes [72,75,90] (Table 2). Increased levels of the H3K9me2 and H3K9me3 repressive marks, were associated with repression of mutL homolog 1 (MLH1), BRCAl, RAD51, RUNX3, Ataxia Telangiectasia Mutated (ATM) and p53-associated KZNF (ZNF 420) protein (APAK) and protein phosphatase 2, catalytic subunit, alpha isoyme (PP2A-C) [74–76,80]. Decreased methylation of H3K4 has been associated with repression of MLH1, BRCAl and RAD51 in hypoxia [75,76]. Hypoxia has also been associated with a global increase in the methylation of histones H3K4, H3K9, H3K27, H3K36 and H3K79 [72,91,92].

Hypoxia-induced changes in histone methylation may result from changes in the expression and activity of histone methyltransferases. Histone methyltransferases catalyze the methylation of lysine or arginine residues on histones. Lysine residues can be mono-, di- or tri-methylated, and the methyltransferases exhibit high specificity with regards to the substrate, the lysine residue and the extent of methylation [93]. Lysine methyltransferases are categorized based on sequence and structure into two families: (1) suppressor of variegation [Su(var)3-9], enhancer of zeste [E(z)], and trithorax (SET)-domain-containing; and (2) disruptor of telomeric silencing-1 (DOT1)-like [4,93]. G9a, suppressor of variegation 3–9 homolog (Suv39h) 1, Suv39h2 and SET domain, bifurcated 1 (SETDB1) are SET-domain containing methyltransferases that have been implicated in the hypoxic response. Hypoxia can lead to the up-regulation of histone methyltransferase G9a, leading to increased levels of H3K9me2 [74,90]. The Suv39h1 and Suv39h2 methyltransferases remain active in hypoxia leading to increased levels of H3K9me3 [94]. The SETDB1 methyltransferase demonstrated a slight increase in protein levels at <0.1% oxygen, and was found to be important for H3K9me3-mediated repression of APAK in hypoxia [79].

On the other hand, hypoxia-induced histone methylation changes may also be affected by histone demethylation. Histone demethylation is carried out by histone demethylases, of which there are two types: Amine-oxidase type Lysine specific demethylases (LSD) and Jumonji C (JmjC)-domain containing oxygenases [95]. Importantly, JmjC dioxygenases require oxygen to function [2,96]. These α-ketoglutarate dependent lysine demethylases have shown oxygen dependence to a certain extent (Table 3) [97], and in 1% oxygen, lack of JmjC demethylase activity can lead to increased histone methylation [92]. In vitro, human Jumonji protein JMJD2E demonstrated an almost linear dependence on oxygen, at oxygen concentrations ranging from 0.5%–20.6% [97]. Further, the Km values of JMJD2A, JMJD2C and JMJD2E for oxygen were found to be approximately equal to cellular oxygen concentration, suggesting that these proteins would be sensitive to changes in oxygen levels [98]. Interestingly, α-ketoglutarate
showed inhibitory effects on JMJD2C at concentrations above 1 mM, which is similar to the α-ketoglutarate levels found in healthy brain tissue [98]. Gliomas and glioblastomas, on the other hand, have α-ketoglutarate at concentrations of 100–300 μM, and JMJD2C demethylase activity was found to be optimal at ~300 μM in vitro suggesting that changes in α-ketoglutarate-levels in cancer cells can also regulate JMJD2C activity [98]. It is also possible that the decreased JmjC demethylase activity in hypoxia may be compensated by increased protein expression [99]. The JmjC demethylases JMJD1A and JMJD2B are targets of HIF transcriptional activation, and were found to be induced at 0.5% oxygen [100]. JMJD2C was also found to be modestly upregulated in hypoxia [100], and at 1% oxygen JMJD2C was shown to interact with HIF1α and promote H3K9me3 demethylation at HREs leading to the optimal transactivation of HIF target genes [101]. HIF-induced JMJD1A expression at 0.5% oxygen caused increased histone demethylation leading to the induction of the adrenomedullin (ADM) and growth and differentiation factor 15 (GDF15) genes, which promote tumor growth in renal and colon cancer cell lines [102]. Another HIF target, JMJD2B demethylase, was shown to regulate histone methylation of H3K9 at 1% oxygen, promoting tumorigenesis [103]. Although JMJD1A and JMJD2B are both HIF1 targets, when tested in 0.2% oxygen, JMJD2B showed decreased activity while JMJD1A remained active [99], suggesting that some JmjC proteins are more tightly regulated by oxygen than others [104]. Increased levels of H3K4-methylation in hypoxia was attributed to inhibition of Jumonji, AT rich interactive domain 1A (JARID1A) demethylase activity [91]. The H3K4-demethylase Lysine-specific histone demethylase 1A (LSD1) does not rely on oxygen but requires flavin adenine dinucleotide (FAD) to function. LSD1 and PLU-1 (also known as JARID1B) can demethylate H3K4 under hypoxic conditions [76], explaining the decrease in H3K4 methylation observed in certain genes in hypoxia (Table 2). Hypoxic cells display a distinct histone methylation profile due to the significant effects on the oxygen-dependent histone demethylases and possibly due to the activity of histone methyltransferases.

Hypoxia-induced epigenetic changes can lead to the down-regulation of tumor suppressors, providing the hypoxic tumor cells with a selective growth advantage. This is consistent with the finding that hypoxia correlates with increased aggressiveness, metastasis and therapy-resistance of tumors. However, hypoxia-induced histone modifications can also lead to the down-regulation of tumor promoting-genes. Recent work by Olcina et al. has described a role for hypoxia-induced H3K9me3 in the repression of APAK, a negative regulator of p53 [79]. H3K9me3-dependent repression of APAK can lead to the induction of p53-dependent apoptosis, which may have both positive and negative effects on the tumor. p53-dependent apoptosis may play a role in blocking the growth of tumors with functional p53 [79]. However, APAK-mediated p53 activation and apoptosis may contribute to the selection of p53-mutant tumor cells [105,106]. This conditional regulation of genes is probably the greatest challenge to developing effective epigenetic therapies. Perhaps with the advent of personalized medicine, specific types of therapies targeting an individual patient’s tumor type and epigenetic spectrum can one day be developed.
Table 3. JmjC demethylases in hypoxia. JmjC family of histone demethylases are thought to require oxygen to mediate catalytic function. However, a number of JmjC proteins are induced in hypoxia and targeted by HIF transcriptional activation, or remain active under certain hypoxic conditions. The human JmjC proteins that are known to be induced in hypoxia and activated by HIF are listed below. Additionally summarized are whether each JmjC protein maintains activity in hypoxia.

| Human JmjC Proteins | Hypoxia-Inducible [Reference] | HIF Target [Reference] | Activity in Hypoxia [Reference] |
|---------------------|-------------------------------|------------------------|---------------------------------|
| KDM2A               | Yes [2]                        |                        |                                 |
| KDM2B               | Yes [2]                        |                        |                                 |
| JHDM1D              | Yes [2]                        |                        |                                 |
| PHF8                | Yes [2]                        |                        |                                 |
| PHF2                | Maybe [2]                      |                        |                                 |
| JMJD8               |                                |                        |                                 |
| KDM3A/JMJD1A        | Yes [2]                        | Yes [100,102]          | Active at 0.2% oxygen [99]     |
| KDM3B               | Yes [2]                        |                        |                                 |
| JMJD1C              | Yes [2]                        |                        |                                 |
| Hairless            |                                |                        |                                 |
| JMJD4               |                                |                        |                                 |
| JMJD6               | Yes [2]                        |                        |                                 |
| HSPBAP1             |                                |                        |                                 |
| HIFAN               | No [2]                         |                        |                                 |
| KDM4C/JMJD2C        | Yes [2]                        | Yes [100]              |                                 |
| KDM4A/JMJD2A        |                                |                        |                                 |
| KDM4B/JMJD2B        | Yes [2]                        | Yes [100,102]          | Inactive at 0.2% oxygen [99]   |
| KDM4D               | Yes [2]                        |                        |                                 |
| KDM4E/JMJD2E        | -                              | -                      | Graded decrease with decreasing levels of oxygen at a range of 0.5%–20.6% oxygen [97] |
| KDM5D               | Yes [2]                        |                        |                                 |
| KDM5C               | Yes [2]                        |                        |                                 |
| KDM5B/JARID1B       | Yes [2]                        | Yes [102]              |                                 |
| KDM5A               |                                |                        |                                 |
| KDM6A               | Yes [2]                        |                        |                                 |
| UTY                 |                                |                        |                                 |
| KDM6B               | Yes [2]                        |                        |                                 |
| JARID2              | Yes [2]                        |                        |                                 |
| JMJD7               |                                |                        |                                 |
| JMJD5               |                                |                        |                                 |

5. Effects of Epigenetic Drugs in Hypoxia

Given the distinct profile of the chromatin landscape in hypoxic tumor cells, and given that the hypoxic cells tend be the most aggressive and therapy-resistant, it is essential to understand the effects of epigenetic drugs in hypoxia. Although DNMT inhibitors have undergone Phase I clinical trials in solid tumors, the efficacy of these drugs against the hypoxic fraction has not been validated. While DNA
Genes 2015, 6

Hypermethylation may play a role in silencing some genes in hypoxia, a global down-regulation of DNMTs and DNA methylation has also been observed [86,87], raising the question of efficacy of DNMT inhibitors under hypoxic conditions. Furthermore, Lachance et al. demonstrated that DNMT3a mediates silencing of endothelial PAS domain protein 1 (EPAS1), which encodes HIF2α, in renal epithelial cells, and that the loss of DNMT3a can lead to the induction of HIF2α, which provides these tumor cells with a selective growth advantage in hypoxia [107]. A switch to the HIF2α hypoxic response can generate tumor stem cell-like properties leading to more aggressive cancers [108]. Given the potential for DNMT3a inhibition to switch towards an aggressive HIF2α hypoxic phenotype, it is important to fully understand the biological consequences of using DNMT inhibitors. This finding highlights the need to test the effects of DNMT inhibitors in hypoxia prior to investigating the efficacy in solid tumor treatment.

The effects of HDAC inhibitors under hypoxic stress have been investigated. While HDAC inhibitors cause histone hyperacetylation, increasing evidence has demonstrated a direct effect on HIF transcription factors in hypoxia, affecting both the expression and function [64]. HDAC4 is known to positively regulate HIF1α under hypoxic stress [109]. Indeed, HDAC inhibitors negatively regulate HIF thereby impeding angiogenesis [63,64]. The HDAC inhibitor Romidepsin (FK228) blocks HIF1α expression and activity in a lung carcinoma model [110], possibly through histone deacetylation, although the mechanism was not tested. Panobinostat, an inhibitor of class I and II HDACs, sensitizes non-small cell lung carcinoma cells to cisplatin [111]. Panobinostat leads to the destabilization of HDACs including HDAC4, which increases open chromatin conformation by increasing the levels of histone acetylation, possibly increasing the sensitivity to cisplatin [111]. Down-regulation of HDAC4 also coincided with increased acetylation and destabilization of HIF1α in hypoxia [111]. In this study, Panobinostat also affected the cells at physiological oxygen levels but the effects were more severe in hypoxia (1% oxygen). Vorinostat has been tested in hepatocellular carcinoma models, in which it was found to affect HIF1α protein translation but not transcription in the presence of hypoxia-mimetic agents [31]. Interestingly, they also observed a decrease in p53 transcript and protein levels upon treatment with Vorinostat [31]. Although HDAC inhibitors negatively regulate HIF and dampen the HIF hypoxic program thereby destabilizing the tumor hypoxic cells, HDAC inhibitors did not have a strong effect against solid tumors in Phase II trials (Table 1). One major hurdle for the use of HDAC inhibitors in solid tumor treatment is the cardiotoxicity observed, and it is possible that this may be overcome by selective delivery of the drug specifically to the region of interest [112]. Additionally, the effects of HDAC inhibitors on the epigenetic profile of the hypoxic tumor cells is not completely known, and investigating the HDAC inhibitor-induced changes in gene expression patterns in hypoxia, may provide additional valuable information.

Histone methylation is significantly impacted by oxygen levels [72,80], primarily due to the reduced activity of certain JmjC histone demethylases (Table 3) which require oxygen to function [2,95]. Consequent increase in histone H3K9-methylation is associated with the repression of a number of genes including tumor suppressors (Table 2). Decreased levels of histone H3K4-methylation has also been linked with silencing of tumor suppressors in hypoxia (Table 2). Although histone methylation may provide a potential means of targeting the hypoxic tumor cells, the biological outcome of this epigenetic mark is still not fully understood, since histone methylation can repress both tumor suppressors and tumor-promoters, such as APAK, as described above. It would be informative to test the effects of targeting histone methylation on gene expression in hypoxia. One method of investigating the effects of histone methylation on gene expression is to inhibit the methyltransferases, and a number of histone
methylenetetrahydrofolate reductase inhibitors have been developed [113]. The Suv39h1 methyltransferase inhibitor, chaetocin, has shown reduced H3K9-methylation and re-expression of tumor suppressors p15 and E-cadherin in AML cells [114], and in human leukemia cells [115]. The LSD1 demethylase inhibitors biguanide and bisguanidine, which are polyamine analogues, showed promising results in colon carcinoma cells [116,117]. These LSD1 inhibitors lead to the re-expression of secreted frizzled-related protein (SFRPs) and GATA family transcription factors, which were silenced in colon cancers, and this was correlated with an increase in H3K4me2 and H3K9-acetylation, and a decrease in H3K9me1 and H3K9me2 [116,117]. Investigating histone methylation as a potential target for future preclinical studies may be beneficial.

It is known that numerous genes are repressed in hypoxia, either though epigenetically regulated transcriptional repression (Table 2) or due to the reduced enzymatic activity of proteins that are oxygen-dependent. Therefore, when developing a compound for solid tumor therapy, it is important to understand whether this target remains active in the most aggressive part of the solid tumor, the hypoxic regions. For instance, several compounds have been in consideration for JmjC inhibition, including Fe(II) and a-ketoglutarate oxygenase inhibitors such as N-oxalyl glycine and its derivatives; and the hydroxamic acid-based HDAC inhibitor Suberoyl Anilide Hydroxamic Acid (SAHA) and its derivatives; and pyridine carboxylates [118]. It is important to note that N-oxalyl glycine and some pyridine carboxylates may also inhibit PHD2 and FIH, which may activate the HIF pathway and confound anti-tumor activity [118]. However, the effectiveness of these JmjC inhibitors on the most aggressive, severely hypoxic tumor cells is uncertain given that some JmjC dioxygenases may already be inactive under these conditions. It is imperative that compounds be tested pre-clinically for efficacy against hypoxic tumor cells before moving on to clinical trials in solid tumors.

6. Conclusions

There has been an increased focus on epigenetic drugs in cancer therapy. While DNMT and HDAC inhibitors have shown promising results against hematological malignancies, they have proven to be less effective against solid tumors. Most, if not all, solid tumors have regions of hypoxia, and, as discussed above, hypoxic tumor cells display a distinct epigenetic profile. In particular, hypoxic tumor cells have increased levels of the repressive histone methylation marks. We propose that when developing epigenetic drugs against solid tumors, given that the most aggressive hypoxic regions of the tumor display a distinct epigenetic profile, it is important to test the effects of these drugs under hypoxic conditions prior to clinical trials. Furthermore, given the global trend towards transcriptional silencing and the reduced function of oxygen-dependent enzymes, such as JmjC demethylases and TET hydroxylases, it is important to understand the epigenetic changes in hypoxia, and the associated biological consequences in order to design effective epigenetic drugs against solid tumors.

Acknowledgments

Many thanks to members of the Hammond lab for critical reading and feedback. Shaliny Ramachandran, Jonathan Ient and Ester M. Hammond are supported by Cancer Research UK (awarded to Ester M. Hammond). Eva-Leonne Göttgens is supported by the Nora Baart Foundation. Adam J. Krieg is supported by the
National Institutes of Health Institutional Development Award (IDeA) under grant number P20GM104936 and by the University of Kansas Endowment.

Author Contributions

Shaliny Ramachandran, Adam J. Krieg and Ester M. Hammond wrote the paper. Shaliny Ramachandran generated Figure 1, Jonathan Ient generated Figure 3 and Eva-Leonne Göttgens generated Figure 2.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Venkatesh, S.; Workman, J.L. Histone exchange, chromatin structure and the regulation of transcription. *Nat. Rev. Mol. Cell Biol.* 2015, 16, 178–189.
2. Melvin, A.; Rocha, S. Chromatin as an oxygen sensor and active player in the hypoxia response. *Cell. Signal.* 2012, 24, 35–43.
3. Kanwal, R.; Gupta, S. Epigenetic modifications in cancer. *Clin. Genet.* 2012, 81, 303–311.
4. Tian, X.; Zhang, S.; Liu, H.M.; Zhang, Y.B.; Blair, C.A.; Mercola, D.; Sassone-Corsi, P.; Zi, X. Histone lysine-specific methyltransferases and demethylases in carcinogenesis: New targets for cancer therapy and prevention. *Curr. Cancer Drug Targets* 2013, 13, 558–579.
5. Cao, R.; Wang, L.; Wang, H.; Xia, L.; Erdjument-Bromage, H.; Tempst, P.; Jones, R.S.; Zhang, Y. Role of histone H3 lysine 27 methylation in polycomb-group silencing. *Science* 2002, 298, 1039–1043.
6. Ning, X.; Shi, Z.; Liu, X.; Zhang, A.; Han, L.; Jiang, K.; Kang, C.; Zhang, Q. DNMT1 and EZH2 mediated methylation silences the microRNA-200B/A/429 gene and promotes tumor progression. *Cancer Lett.* 2015, 359, 198–205.
7. Graham, J.S.; Kaye, S.B.; Brown, R. The promises and pitfalls of epigenetic therapies in solid tumours. *Eur. J. Cancer* 2009, 45, 1129–1136.
8. Blackledge, N.P.; Zhou, J.C.; Tolstorukov, M.Y.; Farcas, A.M.; Park, P.J.; Klose, R.J. CpG islands recruit a histone H3 lysine 36 demethylase. *Mol. Cell* 2010, 38, 179–190.
9. Sarkar, S.; Goldgar, S.; Byler, S.; Rosenthal, S.; Heerboth, S. Demethylation and re-expression of epigenetically silenced tumor suppressor genes: Sensitization of cancer cells by combination therapy. *Epigenomics* 2013, 5, 87–94.
10. Sarkar, S.; Horn, G.; Moulton, K.; Oza, A.; Byler, S.; Kokolus, S.; Longacre, M. Cancer development, progression, and therapy: An epigenetic overview. *Int. J. Mol. Sci.* 2013, 14, 21087–21113.
11. Glasspool, R.M.; Teodoridis, J.M.; Brown, R. Epigenetics as a mechanism driving polygenic clinical drug resistance. *Br. J. Cancer* 2006, 94, 1087–1092.
12. Housman, G.; Byler, S.; Heerboth, S.; Lapinska, K.; Longacre, M.; Snyder, N.; Sarkar, S. Drug resistance in cancer: An overview. *Cancers* 2014, 6, 1769–1792.
13. Jin, W.; Chen, L.; Chen, Y.; Xu, S.G.; Di, G.H.; Yin, W.J.; Wu, J.; Shao, Z.M. UHRF1 is associated with epigenetic silencing of *BRCA1* in sporadic breast cancer. *Breast Cancer Res. Treat.* 2010, 123, 359–373.
14. Zhang, C.; Li, H.; Zhou, G.; Zhang, Q.; Zhang, T.; Li, J.; Zhang, J.; Hou, J.; Liew, C.T.; Yin, D. Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells. J. Pathol. 2007, 212, 134–142.

15. Kim, M.H.; Kim, M.S.; Kim, W.; Kang, M.A.; Cacalano, N.A.; Kang, S.B.; Shin, Y.J.; Jeong, J.H. Suppressor of cytokine signaling (SOCS) genes are silenced by DNA hypermethylation and histone deacetylation and regulate response to radiotherapy in cervical cancer cells. PLoS ONE 2015, 10, e0123133.

16. Kwong, J.; Lo, K.W.; Chow, L.S.; Chan, F.L.; To, K.F.; Huang, D.P. Silencing of the retinoid response gene TIG1 by promoter hypermethylation in nasopharyngeal carcinoma. Int. J. Cancer 2005, 113, 386–392.

17. Wang, T.; Liu, H.; Chen, Y.; Liu, W.; Yu, J.; Wu, G. Methylation associated inactivation of RASSF1A and its synergistic effect with activated K-Ras in nasopharyngeal carcinoma. J. Exp. Clin. Cancer Res. 2009, doi:10.1186/1756-9966-28-160.

18. Tong, J.H.; Ng, D.C.; Chau, S.L.; So, K.K.; Leung, P.P.; Lee, T.L.; Lung, R.W.; Chan, M.W.; Chan, A.W.; Lo, K.W.; et al. Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer 2010, doi:10.1186/1471-2407-10-253.

19. Shu, X.S.; Li, L.; Ji, M.; Cheng, Y.; Ying, J.; Fan, Y.; Zhong, L.; Liu, X.; Tsao, S.W.; Chan, A.T.; et al. FEZF2, a novel 3P14 tumor suppressor gene, represses oncogene EZH2 and MDM2 expression and is frequently methylated in nasopharyngeal carcinoma. Carcinogenesis 2013, 34, 1984–1993.

20. Olcina, M.M.; O’Dell, S.; Hammond, E.M. Targeting chromatin to improve radiation response. Br. J. Radiol. 2015, doi:10.1259/bjr.20140649.

21. Song, S.H.; Han, S.W.; Bang, Y.J. Epigenetic-based therapies in cancer: Progress to date. Drugs 2011, 71, 2391–2403.

22. Nebbioso, A.; Carafa, V.; Benedetti, R.; Altucci, L. Trials with “epigenetic” drugs: An update. Mol. Oncol. 2012, 6, 657–682.

23. Wongtrakoongate, P. Epigenetic therapy of cancer stem and progenitor cells by targeting DNA methylation machineries. World J. Stem Cells 2015, 7, 137–148.

24. Nguyen, C.T.; Weisenberger, D.J.; Velicescu, M.; Gonzales, F.A.; Lin, J.C.; Liang, G.; Jones, P.A. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res. 2002, 62, 6456–6461.

25. Momparler, R.L.; Momparler, L.F.; Samson, J. Comparison of the antileukemic activity of 5-Aza-2'-deoxycytidine, 1-/g533-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia. Leuk. Res. 1984, 8, 1043–1049.

26. Fuks, F.; Burgers, W.A.; Brehm, A.; Hughes-Davies, L.; Kouzarides, T. DNA methyltransferase dnm1t associates with histone deacetylase activity. Nat. Genet. 2000, 24, 88–91.

27. Robertson, K.D.; Ait-Si-Ali, S.; Yokochi, T.; Wade, P.A.; Jones, P.L.; Wolffe, A.P. DNMT1 forms a complex with RB, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat. Genet. 2000, 25, 338–342.

28. Mottamal, M.; Zheng, S.; Huang, T.L.; Wang, G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules 2015, 20, 3898–3941.
29. Mund, C.; Lyko, F. Epigenetic cancer therapy: Proof of concept and remaining challenges. BioEssays News Rev. Mol. Cell. Dev. Biol. 2010, 32, 949–957.
30. Azad, N.; Zahnow, C.A.; Rudin, C.M.; Baylin, S.B. The future of epigenetic therapy in solid tumours—Lessons from the past. Nat. Rev. Clin. Oncol. 2013, 10, 256–266.
31. Hutt, D.M.; Roth, D.M.; Vignaud, H.; Cullin, C.; Boucheecareilh, M. The histone deacetylase inhibitor, vorinostat, represses hypoxia inducible factor 1α expression through translational inhibition. PLoS ONE 2014, 9, e106224.
32. Lee, H.Z.; Kwitkowski, V.E.; del Valle, P.L.; Ricci, M.S.; Saber, H.; Habtemariam, B.A.; Bullock, J.; Bloomquist, E.; Li Shen, Y.; Chen, X.H.; et al. Fda approval: Belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Clin. Cancer Res. 2015, doi:10.1158/1078-0432.CCR-14-3119.
33. Slingerland, M.; Guchelaar, H.J.; Gelderblom, H. Histone deacetylase inhibitors: An overview of the clinical studies in solid tumors. AntiCancer Drugs 2014, 25, 140–149.
34. Molife, L.R.; de Bono, J.S. Belinostat: Clinical applications in solid tumors and lymphoma. Expert Opin. Investig. Drugs 2011, 20, 1723–1732.
35. Brown, J.M.; Giaccia, A.J. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res. 1998, 58, 1408–1416.
36. Vansteenkiste, J.; van Cutsem, E.; Dumez, H.; Chen, C.; Ricker, J.L.; Randolph, S.S.; Schoffski, P. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Investig. New Drugs 2008, 26, 483–488.
37. Luu, T.H.; Morgan, R.J.; Leong, L.; Lim, D.; McNamara, M.; Portnow, J.; Frankel, P.; Smith, D.D.; Doroshow, J.H.; Wong, C.; et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: A California cancer consortium study. Clin. Cancer Res. 2008, 14, 7138–7142.
38. Modesitt, S.C.; Sill, M.; Hoffman, J.S.; Bender, D.P. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study. Gynecol. Oncol. 2008, 109, 182–186.
39. Blumenschein, G.R., Jr.; Kies, M.S.; Papadimitrakopoulou, V.A.; Lu, C.; Kumar, A.J.; Ricker, J.L.; Chiao, J.H.; Chen, C.; Frankel, S.R. Phase II trial of the histone deacetylase inhibitor vorinostat (zolinza, suberoylanilide hydroxamic acid, saha) in patients with recurrent and/or metastatic head and neck cancer. Investig. New Drugs 2008, 26, 81–87.
40. Ramalingam, S.S.; Maitland, M.L.; Frankel, P.; Argiris, A.E.; Koczywas, M.; Gitlitz, B.; Thomas, S.; Espinoza-Delgado, I.; Vokes, E.E.; Gandara, D.R.; et al. Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J. Clin. Oncol. 2010, 28, 56–62.
41. Stadler, W.M.; Margolin, K.; Ferber, S.; McCulloch, W.; Thompson, J.A. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin. Genitourin. Cancer 2006, 5, 57–60.
42. Schrump, D.S.; Fischette, M.R.; Nguyen, D.M.; Zhao, M.; Li, X.; Kunst, T.F.; Hancox, A.; Hong, J.A.; Chen, G.A.; Kruchin, E.; et al. Clinical and molecular responses in lung cancer patients receiving romidepsin. Clin. Cancer Res. 2008, 14, 188–198.
43. Whitehead, R.P.; Rankin, C.; Hoff, P.M.; Gold, P.J.; Billingsley, K.G.; Chapman, R.A.; Wong, L.; Ward, J.H.; Abbruzzese, J.L.; Blanke, C.D. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: A southwest oncology group study (S0336). *Investig. New Drugs* **2009**, *27*, 469–475.

44. Molife, L.R.; Attard, G.; Fong, P.C.; Karavasilis, V.; Reid, A.H.; Patterson, S.; Riggs, C.E., Jr.; Higano, C.; Stadler, W.M.; McCulloch, W.; *et al.* Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACI) romidepsin in metastatic castration-resistant prostate cancer (CRPC). *Ann. Oncol.* **2010**, *21*, 109–113.

45. Otterson, G.A.; Hodgson, L.; Pang, H.; Vokes, E.E. Phase II study of the histone deacetylase inhibitor romidepsin in relapsed small cell lung cancer (cancer and leukemia group B 30304). *J. Thoracic Oncol.* **2010**, *5*, 1644–1648.

46. Giaccone, G.; Rajan, A.; Berman, A.; Kelly, R.J.; Szabo, E.; Lopez-Chavez, A.; Trepel, J.; Lee, M.J.; Cao, L.; Espinoza-Delgado, I.; *et al.* Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. *J. Clin. Oncol.* **2011**, *29*, 2052–2059.

47. Hainsworth, J.D.; Infante, J.R.; Spigel, D.R.; Arrowsmith, E.R.; Boccia, R.V.; Burris, H.A. A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. *Cancer Investig.* **2011**, *29*, 451–455.

48. Wang, H.; Cao, Q.; Dudek, A.Z. Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy. *Anticancer Res.* **2012**, *32*, 1027–1031.

49. Hauschild, A.; Trefzer, U.; Garbe, C.; Kaehler, K.C.; Ugurel, S.; Kiecker, F.; Eigentler, T.; Krissel, H.; Schott, A.; Schadendorf, D. Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-[4-{[2-aminophenyl]-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. *Melanoma Res.* **2008**, *18*, 274–278.

50. Witt, S.E.; Jotte, R.M.; Konduri, K.; Neubauer, M.A.; Spira, A.I.; Ruxer, R.L.; Varella-Garcia, M.; Bunn, P.A., Jr.; Hirsch, F.R. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. *J. Clin. Oncol.* **2012**, *30*, 2248–2255.

51. Juergens, R.A.; Wrangle, J.; Vendetti, J.; Murphy, S.C.; Zhao, M.; Coleman, B.; Sebree, R.; Rodgers, K.; Hooker, C.M.; Franco, N.; *et al.* Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. *Cancer Discov.* **2011**, *1*, 598–607.

52. Candelaria, M.; Gallardo-Rincon, D.; Arce, C.; Cetina, L.; Aguilar-Ponce, J.L.; Arrieta, O.; Gonzalez-Fierro, A.; Chavez-Blanco, A.; de la Cruz-Hernandez, E.; Camargo, M.F.; *et al.* A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. *Ann. Oncol.* **2007**, *18*, 1529–1538.

53. Coronel, J.; Cetina, L.; Pacheco, I.; Trejo-Becerril, C.; Gonzalez-Fierro, A.; de la Cruz-Hernandez, E.; Perez-CARDenas, E.; Taja-Chayeb, L.; Arias-Bofill, D.; Candelaria, M.; *et al.* A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. *Med. Oncol.* **2011**, *28*, S540–S546.

54. Bauman, J.; Verschraegen, C.; Belinsky, S.; Muller, C.; Rutledge, T.; Fekrazad, M.; Ravindranathan, M.; Lee, S.J.; Jones, D. A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies. *Cancer Chemother. Pharmacol.* **2012**, *69*, 547–554.
55. Fu, S.; Hu, W.; Iyer, R.; Kavanagh, J.J.; Coleman, R.L.; Levenback, C.F.; Sood, A.K.; Wolf, J.K.; Gershenson, D.M.; Markman, M.; et al. Phase 1B-2A study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. *Cancer* **2011**, *117*, 1661–1669.

56. Appleton, K.; Mackay, H.J.; Judson, I.; Plumb, J.A.; McCormick, C.; Stratheede, G.; Lee, C.; Barrett, S.; Reade, S.; Jadayel, D.; et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. *J. Clin. Oncol.* **2007**, *25*, 4603–4609.

57. Pohlmann, P.; DiLeone, L.P.; Cancella, A.I.; Caldas, A.P.; Dal Lago, L.; Campos, O., Jr.; Monego, E.; Rivoire, W.; Schwartsmann, G. Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. *Am. J. Clin. Oncol.* **2002**, *25*, 496–501.

58. Hammond, E.M.; Asselin, M.C.; Forster, D.; O’Connor, J.P.; Senra, J.M.; Williams, K.J. The meaning, measurement and modification of hypoxia in the laboratory and the clinic. *Clin. Oncol.* **2014**, *26*, 277–288.

59. Cosse, J.P.; Michiels, C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. *Anti-Cancer Agents Med. Chem.* **2008**, *8*, 790–797.

60. Nordsmark, M.; Bentzen, S.M.; Rudat, V.; Brizel, D.; Lartigau, E.; Stadler, P.; Becker, A.; Adam, M.; Molls, M.; Dunst, J.; et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. *Radiother. Oncol.* **2005**, *77*, 18–24.

61. Semenza, G.L. Hypoxia-inducible factor 1: Master regulator of O₂ homeostasis. *Curr. Opin. Genet. Dev.* **1998**, *8*, 588–594.

62. Nguyen, M.P.; Lee, S.; Lee, Y.M. Epigenetic regulation of hypoxia inducible factor in diseases and therapeutics. *Arch. Pharm. Res.* **2013**, *36*, 252–263.

63. Ellis, L.; Hammers, H.; Pili, R. Targeting tumor angiogenesis with histone deacetylase inhibitors. *Cancer Lett.* **2009**, *280*, 145–153.

64. Liang, D.; Kong, X.; Sang, N. Effects of histone deacetylase inhibitors on HIF-1. *Cell Cycle* **2006**, *5*, 2430–2435.

65. Rankin, E.B.; Giaccia, A.J. The role of hypoxia-inducible factors in tumorigenesis. *Cell Death Differ.* **2008**, *15*, 678–685.

66. Luo, D.; Wang, Z.; Wu, J.; Jiang, C.; Wu, J. The role of hypoxia inducible factor-1 in hepatocellular carcinoma. *BioMed Res. Int.* **2014**, doi:10.1155/2014/409272.

67. Liao, D.; Johnson, R.S. Hypoxia: A key regulator of angiogenesis in cancer. *Cancer Metast. Rev.* **2007**, *26*, 281–290.

68. Albinger-Hegyi, A.; Stoeckli, S.J.; Schmid, S.; Storz, M.; Iotzova, G.; Probst-Hensch, N.M.; Rehrauer, H.; Tinguely, M.; Moch, H.; Hegyi, I. Lysyl oxidase expression is an independent marker of prognosis and a predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC). *Int. J. Cancer* **2010**, *126*, 2653–2662.
69. Le, Q.T.; Harris, J.; Magliocco, A.M.; Kong, C.S.; Diaz, R.; Shin, B.; Cao, H.; Trotti, A.; Erler, J.T.; Chung, C.H.; et al. Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation therapy oncology group trial 90-03. *J. Clin. Oncol.* **2009**, *27*, 4281–4286.

70. Sakai, M.; Kato, H.; Sano, A.; Tanaka, N.; Inose, T.; Kimura, H.; Sohda, M.; Nakajima, M.; Kuwano, H. Expression of lysyl oxidase is correlated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma. *Ann. Surg. Oncol.* **2009**, *16*, 2494–2501.

71. Erler, J.T.; Bennewith, K.L.; Nicolau, M.; Dornhofer, N.; Kong, C.; Le, Q.T.; Chi, J.T.; Jeffrey, S.S.; Giaccia, A.J. Lysyl oxidase is essential for hypoxia-induced metastasis. *Nature* **2006**, *440*, 1222–1226.

72. Johnson, A.B.; Denko, N.; Barton, M.C. Hypoxia induces a novel signature of chromatin modifications and global repression of transcription. *Mutat. Res.* **2008**, *640*, 174–179.

73. Kim, M.S.; Kwon, H.J.; Lee, Y.M.; Baek, J.H.; Jang, J.E.; Lee, S.W.; Moon, E.J.; Kim, H.S.; Lee, S.K.; Chung, H.Y.; et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. *Nature Med.* **2001**, *7*, 437–443.

74. Lee, S.H.; Kim, J.; Kim, W.H.; Lee, Y.M. Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells. *Oncogene* **2009**, *28*, 184–194.

75. Lu, Y.; Chu, A.; Turker, M.S.; Glazer, P.M. Hypoxia-induced epigenetic regulation and silencing of the *BRCA1* promoter. *Mol. Cell. Biol.* **2011**, *31*, 3339–3350.

76. Lu, Y.; Wajapeyee, N.; Turker, M.S.; Glazer, P.M. Silencing of the DNA mismatch repair gene *MLH1* induced by hypoxic stress in a pathway dependent on the histone demethylase LSD1. *Cell Rep.* **2014**, *8*, 501–513.

77. Okami, J.; Simeone, D.M.; Logsdon, C.D. Silencing of the hypoxia-inducible cell death protein BNIP3 in pancreatic cancer. *Cancer Res.* **2004**, *64*, 5338–5346.

78. Murai, M.; Toyota, M.; Suzuki, H.; Satoh, A.; Sasaki, Y.; Akino, K.; Ueno, M.; Takahashi, F.; Kusano, M.; Mita, H.; et al. Aberrant methylation and silencing of the *BNIP3* gene in colorectal and gastric cancer. *Clin. Cancer Res.* **2005**, *11*, 1021–1027.

79. Olcina, M.M.; Leszczynska, K.B.; Senra, J.M.; Isa, N.F.; Harada, H.; Hammond, E.M. H3K9me3 facilitates hypoxia-induced p53-dependent apoptosis through repression of APAK. *Oncogene* **2015**, doi:10.1038/onc.2015.134.

80. Olcina, M.M.; Foskolou, I.P.; Anbalagan, S.; Senra, J.M.; Pires, I.M.; Jiang, Y.; Ryan, A.J.; Hammond, E.M. Replication stress and chromatin context link *ATM* activation to a role in DNA replication. *Mol. Cell* **2013**, *52*, 758–766.

81. Scanlon, S.E.; Glazer, P.M. Hypoxic stress facilitates acute activation and chronic downregulation of fanconi anemia proteins. *Mol. Cancer Res.* **2014**, *12*, 1016–1028.

82. Nakamura, J.; Kitajima, Y.; Kai, K.; Hashiguchi, K.; Hiraki, M.; Noshiro, H.; Miyazaki, K. Expression of hypoxic marker ca ix is regulated by site-specific DNA methylation and is associated with the histology of gastric cancer. *Am. J. Pathol.* **2011**, *178*, 515–524.

83. Huang, K.T.; Mikeska, T.; Dobrovic, A.; Fox, S.B. DNA methylation analysis of the HIF-1α Prolyl hydroxylase domain genes PHD1, PHD2, PHD3 and the factor inhibiting HIF gene FIH in invasive breast carcinomas. *Histopathology* **2010**, *57*, 451–460.
84. Rawluszko, A.A.; Bujnicka, K.E.; Horbacka, K.; Krokowicz, P.; Jagodzinski, P.P. Expression and DNA methylation levels of Prolyl hydroxylases PHD1, PHD2, PHD3 and asparaginyl hydroxylase FIH in colorectal cancer. *BMC Cancer* **2013**, doi:10.1186/1471-2407-13-526.

85. Liu, Q.; Liu, L.; Zhao, Y.; Zhang, J.; Wang, D.; Chen, J.; He, Y.; Wu, J.; Zhang, Z.; Liu, Z. Hypoxia induces genomic DNA demethylation through the activation of HIF-1α and transcriptional upregulation of MAT2A in hepatoma cells. *Mol. Cancer Ther.* **2011**, 10, 1113–1123.

86. Skowronski, K.; Dubey, S.; Rodenhiser, D.; Coomber, B. Ischemia dysregulates DNA methyltransferases and p16INK4a methylation in human colorectal cancer cells. *Epigenetics* **2010**, 5, 547–556.

87. Shahrzad, S.; Bertrand, K.; Minhas, K.; Coomber, B.L. Induction of DNA hypomethylation by tumor hypoxia. *Epigenetics* **2007**, 2, 119–125.

88. Mariani, C.J.; Vasanthakumar, A.; Madzo, J.; Yesilkanal, A.; Bhagat, T.; Yu, Y.; Bhattacharyya, S.; Wenger, R.H.; Cohn, S.L.; Nanduri, J.; et al. Tet1-mediated hydroxymethylation facilitates hypoxic gene induction in neuroblastoma. *Cell Rep.* **2014**, 7, 1343–1352.

89. Hattori, M.; Yokoyama, Y.; Hattori, T.; Motegi, S.I.; Amano, H.; Hatada, I.; Ishikawa, O. Global DNA hypomethylation and hypoxia-induced expression of the ten eleven translocation (TET) family, TET1, in scleroderma fibroblasts. *Exp. Dermatol.* **2015**, doi:10.1111/exd.12767.

90. Chen, H.; Yan, Y.; Davidson, T.L.; Shinkai, Y.; Costa, M. Hypoxic stress induces dimethylated histone H3 lysine 9 through histone methyltransferase G9a in mammalian cells. *Cancer Res.* **2006**, 66, 9009–9016.

91. Zhou, X.; Sun, H.; Chen, H.; Zavadi, J.; Kluz, T.; Arita, A.; Costa, M. Hypoxia induces trimethylated H3 lysine 4 by inhibition of JARID1A demethylase. *Cancer Res.* **2010**, 70, 4214–4221.

92. Tausendschon, M.; Dehne, N.; Brune, B. Hypoxia causes epigenetic gene regulation in macrophages by attenuating Jumonji histone demethylase activity. *Cytokine* **2011**, 53, 256–262.

93. Black, J.C.; van Rechem, C.; Whetstine, J.R. Histone lysine methylation dynamics: Establishment, regulation, and biological impact. *Mol. Cell* **2012**, 48, 491–507.

94. Benlhabib, H.; Mendelson, C.R. Epigenetic regulation of surfactant protein a gene (sp-a) expression in fetal lung reveals a critical role for SUV39H methyltransferases during development and hypoxia. *Mol. Cell. Biol.* **2011**, 31, 1949–1958.

95. Hoffmann, I.; Roatsch, M.; Schmitt, M.L.; Carlino, L.; Pippel, M.; Sippl, W.; Jung, M. The role of histone demethylases in cancer therapy. *Mol. Oncol.* **2012**, 6, 683–703.

96. Yang, J.; Ledaki, I.; Turley, H.; Gatter, K.C.; Montero, J.C.; Li, J.L.; Harris, A.L. Role of hypoxia-inducible factors in epigenetic regulation via histone demethylases. *Ann. N. Y. Acad. Sci.* **2009**, 1177, 185–197.

97. Sanchez-Fernandez, E.M.; Tarhonskaya, H.; Al-Qahtani, K.; Hopkinson, R.J.; McCullagh, J.S.; Schofield, C.J.; Flashman, E. Investigations on the oxygen dependence of a 2-oxoglutarate histone demethylase. *Biochem. J.* **2013**, 449, 491–496.

98. Cascella, B.; Mirica, L.M. Kinetic analysis of iron-dependent histone demethylases: α-ketoglutarate substrate inhibition and potential relevance to the regulation of histone demethylation in cancer cells. *Biochemistry* **2012**, 51, 8699–8701.
99. Beyer, S.; Kristensen, M.M.; Jensen, K.S.; Johansen, J.V.; Staller, P. The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. *J. Biol. Chem.* **2008**, *283*, 36542–36552.

100. Pollard, P.J.; Loenarz, C.; Mole, D.R.; McDonough, M.A.; Gleadle, J.M.; Schofield, C.J.; Ratcliffe, P.J. Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1α. *Biochem. J.* **2008**, *416*, 387–394.

101. Luo, W.; Chang, R.; Zhong, J.; Pandey, A.; Semenza, G.L. Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, E3367–E3376.

102. Krieg, A.J.; Rankin, E.B.; Chan, D.; Razorenova, O.; Fernandez, S.; Giaccia, A.J. Regulation of the histone demethylase jmjd1a by hypoxia-inducible factor 1α enhances hypoxic gene expression and tumor growth. *Mol. Cell. Biol.* **2010**, *30*, 344–353.

103. Fu, L.; Chen, L.; Yang, J.; Ye, T.; Chen, Y.; Fang, J. HIF-1α-induced histone demethylase JMJD2B contributes to the malignant phenotype of colorectal cancer cells via an epigenetic mechanism. *Carcinogenesis* **2012**, *33*, 1664–1673.

104. Hancock, R.L.; Dunne, K.; Walport, L.J.; Flashman, E.; Kawamura, A. Epigenetic regulation by histone demethylases in hypoxia. *Epigenomics* **2015**, *2*, 1–21.

105. Graeber, T.G.; Osmanian, C.; Jacks, T.; Housman, D.E.; Koch, C.J.; Lowe, S.W.; Giaccia, A.J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. *Nature* **1996**, *379*, 88–91.

106. Leszczynska, K.B.; Foskolou, I.P.; Abraham, A.G.; Anbalagan, S.; Tellier, C.; Haider, S.; Span, P.N.; O’Neill, E.E.; Buffa, F.M.; Hammond, E.M. Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT. *J. Clin. Invest.* **2015**, *125*, 2385–2398.

107. Lachance, G.; Uniacke, J.; Audas, T.E.; Holtermann, C.E.; Franovic, A.; Payette, J.; Lee, S. DNMT3A epigenetic program regulates the HIF-2α oxygen-sensing pathway and the cellular response to hypoxia. *Proc. Natl. Acad. Sci. USA* **2014**, *111*, 7783–7788.

108. Koh, M.Y.; Lemos, R., Jr.; Liu, X.; Powis, G. The hypoxia-associated factor switches cells from HIF-1α- to HIF-2α-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. *Cancer Res.* **2011**, *71*, 4015–4027.

109. Geng, H.; Harvey, C.T.; Pittsenbarger, J.; Liu, Q.; Beer, T.M.; Xue, C.; Qian, D.Z. HDAC4 protein regulates HIF1α protein lysine acetylation and cancer cell response to hypoxia. *J. Biol. Chem.* **2011**, *286*, 38095–38102.

110. Mie Lee, Y.; Kim, S.H.; Kim, H.S.; Jin Son, M.; Nakajima, H.; Jeong Kwon, H.; Kim, K.W. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1α activity. *Biochem. Biophys. Res. Commun.* **2003**, *300*, 241–246.

111. Fischer, C.; Leithner, K.; Wohlknoenig, C.; Quehenberger, F.; Bertsch, A.; Olschewski, A.; Olschewski, H.; Hrzenjak, A. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization. *Mol. Cancer* **2015**, doi:10.1186/1476-4598-14-4.

112. Gryder, B.E.; Sodji, Q.H.; Oyelere, A.K. Targeted cancer therapy: Giving histone deacetylase inhibitors all they need to succeed. *Future Med. Chem.* **2012**, *4*, 505–524.

113. Wagner, T.; Jung, M. New lysine methyltransferase drug targets in cancer. *Nat. Biotechnol.* **2012**, *30*, 622–623.
114. Lakshmikuttyamma, A.; Scott, S.A.; de Coteau, J.F.; Geyer, C.R. Reexpression of epigenetically silenced aml tumor suppressor genes by SUV39H1 inhibition. *Oncogene* 2010, 29, 576–588.

115. Tran, H.T.; Kim, H.N.; Lee, I.K.; Nguyen-Pham, T.N.; Ahn, J.S.; Kim, Y.K.; Lee, J.J.; Park, K.S.; Kook, H.; Kim, H.J. Improved therapeutic effect against leukemia by a combination of the histone methyltransferase inhibitor chaetocin and the histone deacetylase inhibitor trichostatin A. *J. Korean Med. Sci.* 2013, 28, 237–246.

116. Huang, Y.; Greene, E.; Murray Stewart, T.; Goodwin, A.C.; Baylin, S.B.; Woster, P.M.; Casero, R.A., Jr. Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. *Proc. Natl. Acad. Sci. USA* 2007, 104, 8023–8028.

117. Huang, Y.; Stewart, T.M.; Wu, Y.; Baylin, S.B.; Marton, L.J.; Perkins, B.; Jones, R.J.; Woster, P.M.; Casero, R.A., Jr. Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. *Clin. Cancer Res.* 2009, 15, 7217–7228.

118. Lohse, B.; Kristensen, J.L.; Kristensen, L.H.; Agger, K.; Helin, K.; Gajhede, M.; Clausen, R.P. Inhibitors of histone demethylases. *Bioorg. Med. Chem.* 2011, 19, 3625–3636.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).